API manufacturer Olon acquires Infa Group

Acquisition expected to double the Italian manufacturer's generics portfolio.

Olon is one of the largest European developers and manufacturers, supplying APIs for the pharmaceutical industry worldwide, for both generics and contract manufacturing.

Olon owns five manufacturing sites in northern Italy (Rodano, Settimo Torinese, Garbagnate Milanese, Mulazzano and Dorno) with more than 800 employees, whereas Infa Group, with more than 400 employees, has two manufacturing sites in Italy (Labochim and Sifavitor) and one in Spain (Derivados Químicos).

The acquisition will broaden and diversify the portfolio by doubling it to more than 200 generic products and will strengthen its CDMO business.

Olon's 2015 revenue was above €200 million. The 2016 total pro-forma revenue, combining Olon and Infa, is expected to exceed €300 million, confirming the birth of a significant player in Europe, as well as in the US.

"The acquisition of Infa will provide an established custom synthesis presence with customers worldwide and will strengthen our generic position by adding a large amount of products positioning Olon as one of the largest player in Europe," said Paolo Tubertini, Olon CEO.

Strategic advantages of the acquisition

The merger of Olon and Infa will expand Olon's products portfolio, which already includes fermented and semi-synthetic APIs, HPAPIs and cytotoxic compounds, controlled substances, retinoids, antivirals, biologics and recombinant peptides.

Olon and Infa will have available about 130 Active US Drug Master Files (DMFs) and more than 50 EU Certificates of Suitability (COS) or Compliance with the European Pharmacopoeia (CEP) and will rely on eight manufacturing facilities self-identified under GDUFA.

The acquisition will strengthen its services to CDMO customers from early clinical phases up to the commercial manufacturing.